Cargando…

The novel atypical antipsychotic cariprazine demonstrates dopamine D(2) receptor‐dependent partial agonist actions on rat mesencephalic dopamine neuronal activity

AIM: Cariprazine, a dopamine D(3)‐preferring D(3)/D(2) receptor partial agonist, is FDA approved for the treatment of schizophrenia and acute manic or mixed episodes of bipolar disorder. This study used in vivo electrophysiological techniques in anesthetized rats to determine cariprazine's effe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Delcourte, Sarah, Ashby, Charles R., Rovera, Renaud, Kiss, Béla, Adham, Nika, Farkas, Bence, Haddjeri, Nasser
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282959/ https://www.ncbi.nlm.nih.gov/pubmed/29729086 http://dx.doi.org/10.1111/cns.12867

Ejemplares similares

Preferential Effects of Cariprazine on Counteracting the Disruption of Social Interaction and Decrease in Extracellular Dopamine Levels Induced by the Dopamine D(3) Receptor Agonist, PD-128907 in Rats: Implications for the Treatment of Negative and Depressive Symptoms of Psychiatric Disorders
por: Kehr, Jan, et al.
Publicado: (2022)

Cariprazine Exhibits Anxiolytic and Dopamine D(3) Receptor-Dependent Antidepressant Effects in the Chronic Stress Model
por: Duric, Vanja, et al.
Publicado: (2017)

Cariprazine exerts antimanic properties and interferes with dopamine D(2) receptor β-arrestin interactions
por: Gao, Yonglin, et al.
Publicado: (2015)

The novel antipsychotic cariprazine stabilizes gamma oscillations in rat hippocampal slices
por: Meier, Maria A., et al.
Publicado: (2020)

Cariprazine alleviates core behavioral deficits in the prenatal valproic acid exposure model of autism spectrum disorder
por: Román, Viktor, et al.
Publicado: (2021)

Effects of cariprazine on extracellular levels of glutamate, GABA, dopamine, noradrenaline and serotonin in the medial prefrontal cortex in the rat phencyclidine model of schizophrenia studied by microdialysis and simultaneous recordings of locomotor activity
por: Kehr, Jan, et al.
Publicado: (2018)

Binding kinetics of cariprazine and aripiprazole at the dopamine D(3) receptor
por: Frank, Annika, et al.
Publicado: (2018)

Computational heterogeneity in the human mesencephalic dopamine system
por: D’Ardenne, Kimberlee, et al.
Publicado: (2013)

Cariprazine, A Dopamine D(2)/D(3) Receptor Partial Agonist, Modulates ABCG2-Mediated Multidrug Resistance in Cancer
por: Hussein, Noor, et al.
Publicado: (2018)

Successful treatment of dopamine dysregulation syndrome with dopamine D(2) partial agonist antipsychotic drug
por: Mizushima, Jin, et al.
Publicado: (2012)

Preferential binding to dopamine D(3) over D(2) receptors by cariprazine in patients with schizophrenia using PET with the D(3)/D(2) receptor ligand [(11)C]-(+)-PHNO
por: Girgis, Ragy R., et al.
Publicado: (2016)

The Effects of Cariprazine and Aripiprazole on PCP-Induced Deficits on Attention Assessed in the 5-Choice Serial Reaction Time Task
por: Barnes, Samuel A., et al.
Publicado: (2018)

Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine
por: Kiss, Béla, et al.
Publicado: (2019)

Correction to: The Effects of Cariprazine and Aripiprazole on PCP-Induced Deficits on Attention Assessed in the 5-Choice Serial Reaction Time Task
por: Barnes, Samuel A., et al.
Publicado: (2018)

Potential Mechanisms for Why Not All Antipsychotics Are Able to Occupy Dopamine D(3) Receptors in the Brain in vivo
por: Kiss, Béla, et al.
Publicado: (2022)

The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
por: Liu, Xiaoshuang, et al.
Publicado: (2019)

Mesencephalic dopamine neurons interfacing the shell of nucleus accumbens and the dorsolateral striatum in the rat
por: Wouterlood, Floris G., et al.
Publicado: (2018)

High dose antipsychotic polypharmacy and dopamine partial agonists - time to rethink guidelines?
por: Reynolds, Gavin P
Publicado: (2021)

Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine
por: Batinic, Borjanka, et al.
Publicado: (2021)

Stress Models of Depression: A Question of Bad Timing
por: Delcourte, Sarah, et al.
Publicado: (2017)

Learned Immobility Produces Enduring Impairment of the HPA Axis Reactivity in Mice without Replicating the Broad Spectrum of Depressive-Like Phenotype
por: Bullich, Sébastien, et al.
Publicado: (2021)

History of the dopamine hypothesis of antipsychotic action
por: Seeman, Mary V
Publicado: (2021)

Structural plasticity in mesencephalic dopaminergic neurons produced by drugs of abuse: critical role of BDNF and dopamine
por: Collo, Ginetta, et al.
Publicado: (2014)

Transplantation site influences the phenotypic differentiation of dopamine neurons in ventral mesencephalic grafts in Parkinsonian rats
por: Fjodorova, Marija, et al.
Publicado: (2017)

Dopamine Agonists and Pathologic Behaviors
por: Kelley, Brendan J., et al.
Publicado: (2012)

Dopamine Agonists for Pituitary Adenomas
por: Cooper, Odelia, et al.
Publicado: (2018)

Search for novel antipsychotic drugs: dopamine forever?
por: Gyertyán, István
Publicado: (2009)

The effects of dopamine and dopamine receptor agonists on the phototransduction cascade of frog rods
por: Nikolaeva, Darya A., et al.
Publicado: (2019)

The Absence of CD47 Promotes Nerve Fiber Growth from Cultured Ventral Mesencephalic Dopamine Neurons
por: Marschinke, Franziska, et al.
Publicado: (2012)

Long 3'UTR of Nurr1 mRNAs is targeted by miRNAs in mesencephalic dopamine neurons
por: Pereira, Luis Alberto, et al.
Publicado: (2017)

Immunolocalization of kappa opioid receptors in the axon initial segment of a group of embryonic mesencephalic dopamine neurons
por: Escobar, Angélica Pilar, et al.
Publicado: (2022)

Effects of Dopamine D(2) Receptor Partial Agonist Antipsychotic Aripiprazole on Dopamine Synthesis in Human Brain Measured by PET with L-[β-(11)C]DOPA
por: Ito, Hiroshi, et al.
Publicado: (2012)

SUN-444 Efficacy and Safety of Dopamine Agonists in Psychiatric Patients Treated with Antipsychotics and Presenting a Macroprolactinoma
por: Allard, Lucie, et al.
Publicado: (2019)

Dopamine-Depleted Dopamine Transporter Knockout (DDD) Mice: Dyskinesia with L-DOPA and Dopamine D1 Agonists
por: Pogorelov, Vladimir M., et al.
Publicado: (2023)

Dopamine modulates the retinal clock through melanopsin-dependent regulation of cholinergic waves during development
por: Kinane, Chaimaa, et al.
Publicado: (2023)

Dopamine dysregulation syndrome after prescription of dopamine agonists: a case report
por: Costa, M.L., et al.
Publicado: (2022)

The treatment of Parkinson's disease with dopamine agonists
por: Konta, Brigitte, et al.
Publicado: (2008)

Impulse control disorders and dopamine agonists
por: Martins, D., et al.
Publicado: (2021)

Experience with Dopamine Agonists in the Treatment of Prolactinomas
por: Barabash, Nadiya Ye., et al.
Publicado: (2022)

Beyond Dopamine: Glutamate as a Target for Future Antipsychotics
por: Sendt, Kyra-Verena, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_g47mgfo4uvgbpslseihs8lj45d